• Optimi Health completed quality release of a single cGMP batch of 5 mg psilocybin capsules to supply a new Canadian Phase 2 trial.
• Study is a multisite, open-label trial in up to 200 people with major depressive disorder using one supervised dose.
• Results have not been presented; patient dosing is expected to finish by end-2027, with data intended to support future registration filings.
• The same batch will also supply Australian licensed clinics prescribing the product for treatment-resistant depression under the Authorised Prescriber Scheme.
• Optimi noted psilocybin-assisted therapy for major depressive disorder remains under investigation, with no Health Canada market authorization for its psilocybin products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006184), on September 23, 2026, and is solely responsible for the information contained therein.